We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

CG Oncology Inc (CGON) USD0.0001

Sell:$31.43 Buy:$31.46 Change: $0.68 (2.12%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
Change: $0.68 (2.12%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
Change: $0.68 (2.12%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Contact details

400 Spectrum Center Drive, Suite 2040
United States
+1 (949) 2886298

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.26 billion
Shares in issue:
66.64 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Arthur Kuan
    Chairman of the Board, Chief Executive Officer
  • Ambaw Bellete
    President, Chief Operating Officer
  • Stephen Dipalma
    Chief Financial Officer
  • Vijay Kasturi
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.